209 related articles for article (PubMed ID: 19801443)
1. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.
Sridhar K; Ross DT; Tibshirani R; Butte AJ; Greenberg PL
Blood; 2009 Nov; 114(23):4847-58. PubMed ID: 19801443
[TBL] [Abstract][Full Text] [Related]
2. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
5. Expression of Rap1GAP in human myeloid disease following microarray selection.
Qi X; Chen Z; Qian J; Cen J; Gu M
Genet Mol Res; 2008 Apr; 7(2):379-87. PubMed ID: 18551404
[TBL] [Abstract][Full Text] [Related]
6. Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome.
Vasikova A; Budinska E; Belickova M; Cermak J; Bruchova H
Neoplasma; 2009; 56(4):335-42. PubMed ID: 19469654
[TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells.
Im H; Rao V; Sridhar K; Bentley J; Mishra T; Chen R; Hall J; Graber A; Zhang Y; Li X; Mias GI; Snyder MP; Greenberg PL
Leuk Lymphoma; 2018 Dec; 59(12):2952-2962. PubMed ID: 29616851
[TBL] [Abstract][Full Text] [Related]
8. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Verma A; Norbury CJ; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Leukemia; 2010 Apr; 24(4):756-64. PubMed ID: 20220779
[TBL] [Abstract][Full Text] [Related]
9. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
11. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Hellström-Lindberg E; Wainscoat JS
Br J Haematol; 2007 Nov; 139(4):578-89. PubMed ID: 17916100
[TBL] [Abstract][Full Text] [Related]
13. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
Pellagatti A; Cazzola M; Giagounidis AA; Malcovati L; Porta MG; Killick S; Campbell LJ; Wang L; Langford CF; Fidler C; Oscier D; Aul C; Wainscoat JS; Boultwood J
Blood; 2006 Jul; 108(1):337-45. PubMed ID: 16527891
[TBL] [Abstract][Full Text] [Related]
17. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities.
Gurney M; Patnaik MM; Hanson CA; Litzow MR; Al-Kali A; Ketterling RP; Tefferi A; Gangat N
Br J Haematol; 2017 Jul; 178(1):57-60. PubMed ID: 28419466
[TBL] [Abstract][Full Text] [Related]
18. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Dostalova Merkerova M; Krejcik Z; Votavova H; Belickova M; Vasikova A; Cermak J
Eur J Hum Genet; 2011 Mar; 19(3):313-9. PubMed ID: 21150891
[TBL] [Abstract][Full Text] [Related]
19. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
20. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
Mills KI; Kohlmann A; Williams PM; Wieczorek L; Liu WM; Li R; Wei W; Bowen DT; Loeffler H; Hernandez JM; Hofmann WK; Haferlach T
Blood; 2009 Jul; 114(5):1063-72. PubMed ID: 19443663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
